Beverly C. Handy, MD, MS
Department of Laboratory Medicine, Division of Pathology-Lab Medicine Div
Present Title & Affiliation
Primary Appointment
Professor - Non Tenured, Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas
Professor - Non Tenured, Laboratory Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas
Education & Training
Degree-Granting Education
| 1992 | The University of Texas Medical School Houston, Houston, Texas, US, MD |
| 1987 | St. Mary's University, San Antonio, Texas, US, Industrial Psychology, M.S |
| 1980 | United States Air Force Academy, Colorado Springs, Colorado, US, Behavioral Sciences, BS |
Postgraduate Training
| 1998-1999 | Clinical Fellowship, Chemical Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas |
| 1992-1997 | Pathology Resident, The University of Texas Health Science Center, San Antonio, Texas |
Licenses & Certifications
| 1999 | Chemical Pathology, American Board of Pathology |
| 1997 | Anatomic and Clinical Pathology, American Board of Pathology |
| 1993 | Texas Medical License |
Experience & Service
Faculty Academic Appointments
Associate Professor-Non Tenured, Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, 2015 - 2018
Associate Professor-Non Tenured, Laboratory Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, 2008 - 2018
Assistant Professor-Non Tenured, Laboratory Medicine, The University of Texas M. D. Anderson Cancer Center, Houston, TX, 2002 - 2008
Instructor-Non Tenured, Laboratory Medicine, The University of Texas M. D. Anderson Cancer Center, Houston, TX, 1999 - 2002
Administrative Appointments/Responsibilities
Quality Officer, Laboratory Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, 2012 - 2015
Director, Tumor Marker Laboratory, Laboratory Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, 2010 - Present
Program Director, Chemical Pathology Fellowship Program, Laboratory Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, 2001 - Present
Other Professional Positions
Chief Resident, Anatomic and Clinical Pathology Program, The University of Texas Health Science Center, San Antonio, TX, 1997
Alternate Voting Member, Instituional Review Committee Wilford Hall United States Air Force Medical Center, San Antonio, TX, 1985
Captain, Chief of Special Counseling, 1984 - 1986
Lieutenant (second and first), Occupational Analyst, 1980 - 1984
Extramural Institutional Committee Activities
Member, Department of Pathology and Laboratory Medicine Working Group on Mentoring, The University of Texas MD Anderson Cancer Center, 2023 - Present
Chair, Clinical Faculty Review Committee, The University of Texas MD Anderson Cancer Center, 2022 - 2023
Member, Clinical Genomics and Biomarker Council, Division of Pathology and Laboratory Medicine, The University of Texas MD Anderson Cancer Center, 2022 - Present
Member, Beaker Software Installation Committee – Special Chemistry, The University of Texas MD Anderson Cancer Center, 2022 - 2023
Member, Beaker Software Installation Committee – Steering Committee, The University of Texas MD Anderson Cancer Center, 2022 - 2023
Member, Beaker Software Installation Committee – Core Laboratory, The University of Texas MD Anderson Cancer Center, 2022 - 2023
Member, Beaker Software Installation Committee – Clinical Pathology, The University of Texas MD Anderson Cancer Center, 2022 - 2023
Member, Strategic Operational Priority Working Group, Division of Pathology and Laboratory Medicine, The University of Texas MD Anderson Cancer Center, 2022
Vice Chair, Clinical Faculty Review Committee, The University of Texas MD Anderson Cancer Center, 2021 - 2022
Member, Clinical Faculty Review Committee, The University of Texas MD Anderson Cancer Center, 2020 - 2023
Member, Faculty Achievement Awards Committee, Faculty Senate, The University of Texas MD Anderson Cancer Center, 2015 - 2017
Member, Acute and Critical Care Subcommittee, The University of Texas MD Anderson Cancer Center, 2013 - 2019
Member, Order Set Task Force, The University of Texas MD Anderson Cancer Center, 2013
Member, Faculty Welfare Committee, Faculty Senate, The University of Texas MD Anderson Cancer Center, 2012
Member, Quality Improvement Assessment Board, The University of Texas MD Anderson Cancer Center, 2011 - Present
Member, Physician Notification Policy Committee, The University of Texas MD Anderson Cancer Center, 2011
Member, Trainee Excellence Award Subcommittee, Alumni and Faculty Association Steering Committee, The University of Texas MD Anderson Cancer Center, 2010 - 2016
Member, Clinical Effectiveness Subcommittee, Metrics Task Force, The University of Texas MD Anderson Cancer Center, 2010
Member, Ad Hoc Committee for Exigency, Faculty Senate, The University of Texas MD Anderson Cancer Center, 2009 - 2010
Member, Clinical Effectiveness Subcommittee, The University of Texas MD Anderson Cancer Center, 2008 - Present
Member, Membership/Bylaws Subcommittee, Alumni and Faculty Association Steering Committee, The University of Texas MD Anderson Cancer Center, 2008 - 2016
Department Liaison, Laboratory Medicine Chair Search Committee, The University of Texas MD Anderson Cancer Center, 2007
Member, Faculty Senate, The University of Texas MD Anderson Cancer Center, 2006 - 2012
Member, Distinguished Alumnus Subcommittee, Alumni and Faculty Association Steering Committee, The University of Texas MD Anderson Cancer Center, 2005 - 2016
Member, OncoLog Editorial Board, The University of Texas MD Anderson Cancer Center, 2004 - 2016
Member, Division of Pathology and Laboratory Medicine Steering Committee, The University of Texas MD Anderson Cancer Center, 2002 - 2019
Member, Alumni and Faculty Association Steering Committee, The University of Texas MD Anderson Cancer Center, 2002 - 2016
Member, Multidisciplinary Evidence-Based Practice Review Committee, The University of Texas MD Anderson Cancer Center, 2002
Member, General Laboratory Software Project Team (Department of Laboratory Medicine), The University of Texas MD Anderson Cancer Center, 2001 - 2004
Member, The University of Texas M. D. Anderson Cancer Center Intensive Care Unit Subcommittee, The University of Texas MD Anderson Cancer Center, 2001 - 2004
Editorial Activities
Ad Hoc Reviewer, Therapeutic Innovation & Regulatory Science
Ad Hoc Reviewer, Discovery Oncology
Ad Hoc Reviewer, The Journal of Applied Laboratory Medicine
Ad Hoc Reviewer, Lab Medicine
Ad Hoc Reviewer, Endocrine, Metabolic and Immune Disorders – Drug Targets
Ad Hoc Reviewer, Clinica Chimica Acta
Ad Hoc Reviewer, Biochemistry Research International
Honors & Awards
| 2021 | Faculty Recognition Award for Excellence in Patient Care, Division of Pathology and Laboratory Medicine, The University of Texas MD Anderson Cancer Center |
| 2008 | The University of Texas M.D. Anderson Cancer Center Sharon K. Martin Award for Performance Improvement Excellence - First Place Prize, 10/10/2008, The University of Texas M. D. Anderson Cancer Center |
| 2004 | Outstanding Educator, The University of Texas M. D. Anderson Cancer Center |
| 1999 | Paul E. Strandjord Young Investigator Award |
| 1992 - 2024 | Alpha Omega Alpha (A.O.A.) Honor Medical Society |
| 1985 | Junior Officer of the Quarter, 3507th Airmen Classification Squadron US Air Force |
| 1984 | Commendation Medal, United States Air Force |
| 1983 | Junior Officer of the Quarter, U.S. Air Force Occupational Measurement Center, United States Air Force |
| 1980 - 1981 | Randolph Air Force Base Varsity Running Team |
| 1980 | National Collegiate Athletic Association Regional Champion |
| 1980 | Lackland Air Force Base Pacesetter Award, United States Air Force |
| 1980 | Most Valuable Player, U.S. Air Force Academy Varsity Rifle Team, United States Air Force |
| 1977 | Marksmanship Ribbon, United States Air Force |
Professional Memberships
Selected Presentations & Talks
Local Presentations
- 2009. Biomarkers for Cardiovascular Assessment. Conference. School of Health Professions. Houston, TX, US.
- 2006. Immunoassay of Human Chorionic Gonadotropin (hCG). Conference. The University of Texas M.D. Anderson Cancer Center. Houston, TX, US.
- 2005. Role of PSA and Other Prostate Cancer-Specific Markers in the 21st Century, Urologic Oncology: Advances in Clinical Practice Conference. Conference. The University of Texas M.D. Anderson Cancer Center. Houston, TX, US.
- 2004. Monoclonal Gammopathies. Conference. Texas Association for Clinical Laboratory Scientists. Houston, TX, US.
- 2003. Laboratory Evaluation of Patients with Monocloncal Proteins. Conference. Philippine Association of Medical Technologists. Houston, TX, US.
- 2002. Current Trends in Cardiac Marker Testing. Conference. Philippine Association of Medical Technologists. Houston, TX, US.
- 2001. Non-Invasive and Minimally Invasive Testing in the Point-of-Care Setting. Conference. Texas Association of Clinical Laboratory Scientists. Houston, TX, US.
- 2001. Changes in Cardiac Marker Testing. Conference. The University of Texas M.D. Anderson Cancer Center. Houston, TX, US.
Regional Presentations
- 2012. Parathyroid Hormone (PTH) Assays. Conference. University of Texas MD Anderson Cancer Center, US.
- 1996. A Recurrent Carotid Body Tumor. Conference. San Antonio Society of Pathologist. San Antonio, TX, US.
National Presentations
- 2017. Validation of the Elecsys BRAHMS Procalcitonin Assay in Patients with Severe Sepsis or Septic Shock. Oral abstract (Research Snapshot – Sepsis XV) presentation. Conference. Society of Critical Care Medicine Annual Meeting, Honolulu Hawaii. Honolulu, HI, US.
- 2010. The Clinical Utility of Circulating Tumor Cell Analysis: What Have We Learned So Far?. Invited. Cambridge Health Institute's Biomarker Assay Development Meeting. San Diego, CA, US.
- 2009. The Clinical Utility of Circulating Tumor Cell Analysis: What Have We Learned So Far?. Invited. Cambridge Health Institute's Accelerating Development and Advancing Personalized Therapy (ADAPT) 2009 Congress. D.C, WA, US.
- 2007. The Role of the Clinical Laboratory in the Management of Cancer Patients - Tumor Markers. Invited. Annual Meeting, Clinical Pathology Symposium, American Society of Clinical Pathologists (ASCP). New Orleans, LA, US.
- 2005. The Role of the Clinical Laboratory in the Management of Cancer Patients - Clinical Chemistry Testing in the Cancer Patient Population. Annual Meeting. Invited. Clinical Pathology Symposium, American Society of Clinical Pathologist (ASCP). Seattle, WA, US.
- 2005. Roundtable, Serum Free Light Chain Assessment in Patients with Monoclonal Gammopathies. Invited. National Meeting, Clinical Ligand Assay Society. San Diego, CA, US.
- 2003. The Laboratory Evaluation of Patients with Monoclonal Gammopathies. Invited. National Teleconference Presentation. American Society of Clinical Pathologist (ASCP), US.
- 2003. Evaluation of Serum for Determination of Potassium Values in a Cancer Patient Population. Conference. ASCP - Annual Meeting (Poster Presentation), American Society of Clinical Pathologists (ASCP). New Orleans, LA, US.
- 1999. Estimating Fosphenytoin Concentration in the Presence of Phenytoin Using Phenytoin Immunoassays and Alkaline Phosphatase. Invited. Annual Meeting, Academy of Clinical Laboratory Physicians & Scientists. Birmingham, AL, US.
- 1994. Retrospective Analysis to Determine the Diagnostic Value of Serum Ferritin in a Specific Patient Population. Conference. ASCP - Annual Meeting (Poster Presentation), American Society of Clinical Pathologists (ASCP). Seattle, WA, US.
International Presentations
- 2013. The Role of Cytokines in Cancer. Invited. BIT's Major Diseases Clinical Summit. Warsaw, PL.
- 2011. Circulating Tumor Cells - A Growing Recognition of Their Clinical Implications. Invited. The 5th China Medicinal Biotech Forum. Beijing, CN.
- 2010. Circulating Tumor Cells - Clinical Relevance and Applications. Invited. BIT's 3rd Annual World Cancer Congress, 2010 - Breast Cancer Conference. Shanghai, CN.
- 2007. Usage of Serum Tumor Markers in Testicular Germ Cell Tumors. Invited. Asia Pacific Evidence-Based Medicine Network Conference. (ROC), TW.
- 2007. Updates on Serum Free Light Chain Assessment in Patients with Monoclonal Gammopathies. Invited. Roundtable, International Meeting, Clinical Ligand Assay Society, PR.
Formal Peers
- 2005. Pathology Grand Rounds, An Update-Serum PSA Testing. Invited. Galveston, TX, US.
Grant & Contract Support
| Date: | 2023 - Present |
| Title: | Clinical Validation Center for Early Detection of Ovarian Cancer with a Multiple Marker Algorithm |
| Funding Source: | NIH/NCI |
| Role: | COLLABORATOR |
| ID: | 5U01CA200462-07 |
| Date: | 2015 - 2022 |
| Title: | Early Detection of Ovarian Cancer with Tumor Associated Proteins and Autoantibodies |
| Funding Source: | CPRIT |
| Role: | Collaborator |
| ID: | RP160145 |
Selected Publications
Peer-Reviewed Articles
- Han, CY, Lu, KH, Corrigan, G, Perez, A, Kohring, SD, Celestino, J, Bedi, DG, Bedia, E, Bevers, TB, Boruta II, DM, Carlson, M, Holman, LL, Leeds, L, Mathews, C, McCann, G, Moore, RG, Schlumbrecht, MP, Slomovitz, BM, Tobias, DH, Williams-Brown, Y, Bevers, MW, Liu, J, Gornet, T, Handy, BC, Lu, Z, Bedia, JS, Skates, S, Bast Jr, RC. Normal Risk Ovarian Screening Study. Journal of Clinical Oncology 42(10):1102-1109, 2024. e-Pub 2024. PMID: 38194613.
- Young Han, C, Bedia, JS, Yang, W, Hawley, S, Bergan, L, Hopper, M, Celestino, J, Guo, J, Gornet, T, Soosaipillai, A, Yang, H, Doskocil, S, Lokshin, A, Handy, BC, Diamandis, EP, Moore, RG, Lu, KH, Lu, Z, Anderson, KS, Drescher, CW, Skates, S, Bast Jr, RC. Autoantibodies, antigen-autoantibody complexes and antigens complement CA125 for early detection of ovarian cancer. British journal of cancer 130(5):861-868, 2024. e-Pub 2024. PMID: 38195887.
- Wang W, Ding Y, Campbell A, Handy BC, Medeiros LJ, Lin P. Biclonal presentation of lymphoplasmacytic lymphoma / Waldenstrom macroglobulinemia. Pathology 51(3):340-343, 2019. e-Pub 2019. PMID: 30846229.
- Cao L, Handy BC, Lee HL, Ning J, Wagar EA, Meng QH. Combination of prostate cancer antigen 3 and prostate-specific antigen improves diagnostic accuracy in men at risk of prostate cancer. Archives of Pathology & Laboratory Medicine. Arch Pathol Lab Med 142(9):1106-1112, 2018. e-Pub 2018. PMID: 29547000.
- Peacock WF, Baumann BM, Bruton D, Davis TE, Handy B, Jones CW, Hollander JE, Limkakeng AT, Mehrotra A, Than M, Ziegler A, Dinkel C. Efficacy of High-Sensitivity Troponin T in Identifying Very-Low-Risk Patients with Possible Acute Coronary Syndrome. JAMA Cardiology 3(2):104-111, 2018. e-Pub 2018. PMID: 29238804.
- Xu JY, Handy B, Michaelis CL, Waguespack SG, Hu MI, Busaidy N, Jimenez C, Cabanillas ME, Fritsche HA, Cote GJ, Sherman SI. Detection and Prognostic Significance of Circulating Tumor Cells in Patients With Metastatic Thyroid Cancer. Journal of Clinical Endocrinology & Metabolism 101(11):4461-4467, 2016. e-Pub 2016. PMID: 27575943.
- Cao L, Chen M, Phipps RA, Del Guidice RE, Handy BC, Wagar EA, Meng QH. Causes and impact of specimen rejection in a clinical chemistry laboratory. Clinica Chimica Acta 458:154-8, 2016. e-Pub 2016. PMID: 27166198.
- Giuliano M, Giordano A, Jackson S, De Giorgi U, Mego M, Cohen EN, Gao H, Anfossi S, Handy BC, Ueno NT, Alvarez RH, De Placido S, Valero V, Hortobagyi GN, Reuben JM, Cristofanilli M. Circulating tumor cells as early predictors of metastatic spread in breast cancer patients with limited metastatic dissemination. Breast Cancer Research 16(5):440, 2014. e-Pub 2014. PMID: 25223629.
- Meng QH, Handy B, Wagar E. A case of green blood. Clinical Chemistry 60(4):695 - 696, 2014. e-Pub 2014. PMID: 24682689.
- Alexanian R, Wang M, Delasalle K, Wang S, Qazilbash M, Handy B, Weber D. Value of novel agents and intensive therapy for patients with multiple myeloma. Transplantation 49(3):422 - 425, 2014. e-Pub 2014. PMID: 24317125.
- Meng QH, Handy BC, Wagar EA. It's not easy being blue-green. Ann Lab Med 33(6):457-458, 2013. e-Pub 2013. PMID: 24205497.
- Dean-Colomb W, Hess KR, Young E, Gornet TG, Handy BC, Moulder SL, Ibrahim N, Pusztai L, Booser D, Valero V, Hortobagyi GN, Esteva FJ. Elevated serum P1NP predicts development of bone metastasis and survival in early-stage breast cancer. Breast Cancer Res Treat 137(2):631 - 636, 2013. e-Pub 2013. PMID: 23242617.
- Paxton RJ, Garcia-Prieto C, Berglund M, Hernandez M, Hejek RA, Handy BC, Brown J, Jones LA. A randomized parallel-group dietary study for stage II-IV ovarian cancer survivors. Gynecologic Oncology 124:410 - 416, 2012. e-Pub 2012. PMID: 22119991.
- Giordano A, Giuliano M, De Laurentiis M, Arpino G, Jackson S, Handy BC, Ueno NT, Andreopoulou E, Alvarez RH, Valero V, De Placido S, Hortobagyi GN, Reuben JM, Cristofanilli M. Circulating tumor cells in immunohistochemical subtypes of metastatic breast cancer: lack of prediction in HER2-positive disease treated with targeted therapy. Annals of Oncology 23(5):1144 - 1150, 2012. e-Pub 2012.
- Mego M, De Giogi U, Dawood S, Wang X, Valero V, Andreopoulou E, Handy BC, Ueno NT, Reuben JM, Cristofanilli M. Characterization of metastatic breast cancer patients with non-detectable circulating tumor cells. International Journal of Cancer 129(2):417-23, 2011. e-Pub 2011.
- Saenger AK, Beyrau R, Braun S, Cooray R, Dolci A, Freidank H, Giannitsis E, Gustafson S, Handy BC, Katus H, Melanson SE, Panteghini M, Venge P, Zorn M, Jarolim P, Bruton D, Jarausch J, Jaffe AS. Multi-center analytical evaluation of high-sensitivity troponin T assay. Clinica Chimica Acta 412(9-10):748-754, 2011. e-Pub 2011.
- Giuliano M, Giordano A, Jackson S, Hess KR, De Giorgi U, Mego M, Handy BC, Ueno NT, Alvarez RH, De Laurentiis M, De Placido S, Valero V, Hortobagyi GN, Reuben JM, Cristofanilli M. Circulating tumor cells as prognostic and predictive markers in metastatic breast cancer patients receiving first-line systemic treatment. Breast Cancer Research 13(3):R67, 2011. e-Pub 2011.
- De Giorgi U, Mego M, Rohren EM, Liu P, handy BC, Reuben JM, Macapinlac HA, Hortobagyi GN, Cristofanilli M, Ueno NT. 18F-FDG PET/CT findings and circulating tumor cell counts in the monitoring of systemic therapies for bone metastases from breast cancer. Journal of Nuclear Medicine 51(8):1213-1218, 2010. e-Pub 2010.
- De Giorgi U, Valero V, Rohren E, Doyle G, Miller C, Ueno N, Handy B, Reuben J, Macapinlac H, Hortobagyi G, Cristofanilli M. Circulating tumor cells and bone metastases as detected by FDG/PET/CT in patients with metastatic breast cancer. Annals of Oncology 21(1):33-39, 2010. e-Pub 2010.
- Wang M, Delasalle K, Feng L, Thomas S, Giralt S, Qazilbash M, Handy B, Lee JJ, Alexanian R. CR represents an early index of potential long survival in multiple myeloma. Bone Marrow Transplantation 45(3):498-504, 2010. e-Pub 2010.
- Mego M, Giorgi U D, Broglio K, Dawood S, Valero V, Andreopoulou E, Handy BC, Reuben J M, Cristofanilli M. Circulating tumour cells are associated with increased risk of venous thromboembolism in metastatic breast cancer patients. British Journal of Cancer 101(11):1813-1816, 2009. e-Pub 2009. PMID: 19888227.
- De Giorgi U, Valero V, Rohren E, Dawood S, Ueno N, Doyle G, Jackson S, Andreopoulu E, Handy BC, Reuben JM, Fritsche HA, Macapinlac H, Hortobagyi GN, Cristofanilli M. Circulating tumor cells and [18F] fluorodeoxyglucose positron emission tomography/computed tomography for outcome prediction in metastatic breast cancer. Journal of Clinical Oncology 27(20):3303 - 11, 2009. e-Pub 2009.
- Iancu DM, Handy BC. The value of laboratory medicine (Part 3). ADVANCE for Administrators of the Laboratory:60-66, 2009. e-Pub 2009.
- Iancu DM, Handy BC. The value of laboratory medicine (Part 2). ADVANCE for Administrators of the Laboratory:53-56, 2009. e-Pub 2009.
- Iancu DM, Handy BC. The value of laboratory medicine (Part 1). ADVANCE for Administrators of the Laboratory:61-62, 2009. e-Pub 2009.
- Mego M, De Giorgi U, Dawood S, Valero V, Andreopoulou E, Handy B, Cristofanilli M. Circulating tumor cells are associated with increased risk of venous thromboembolism in metastatic breast cancer patients. British Journal of Cancer 101(11):1813-1816, 2009. e-Pub 2009.
- Dawood S, Broglio K, Valero V, Reuben J, Handy B, Islam R, Jackson S, Hortobagyi GN, Fritsche H, Cristofanilli M. Circulating tumor cells in metastatic breast cancer; from prognostic stratification to modification of the staging system?. Cancer 113(9):2422-30, 2008. e-Pub 2008.
- Davis JW, Nakanishi H, Kumar V, Bhadkamkar VA, McCormack R, Fritsche HA, Handy BC, Gornet T, Babaian J. Circulating tumor cells in peripheral blood samples from patients with an elevated serum PSA - Initial results of the Cellsearch test in early prostate cancer. The Journal of Urology 179(6):2187-2191, 2008. e-Pub 2008.
- Wang M, Giralt S, Delasalle K, Handy BC, Alexanian R. Bortezomib in combination with thalidomide-dexamethasone for previously untreated multiple myeloma. Hematology 12(3):235-239, 2007. e-Pub 2007.
- Yin CC, Lin P, Carney DA, Handy BC, Rassidakis GZ, Admirand JH, Keating MJ, Medeiros LJ. Chronic lymphocytic leukemia/small lymphocytic lymphoma associated with IgM paraprotein. A clinical pathological study of 26 cases, American Journal of Clinical Pathology 123:594-602, 2005. e-Pub 2005. PMID: 15743747.
- Handy BC, Shen Y. Evaluation of potassium values in a cancer patient population. Laboratory Medicine 36:95-97, 2005. e-Pub 2005.
- Lin P, Hao S, Handy BC, Bueso-Ramos CE, Medeiros LJ. Lymphoid neoplasms associated with IgM paraprotein: a study of 382 patients. American Journal of Clinical Pathology 123:200-205, 2005. e-Pub 2005. PMID: 15842043.
- Paul S, Karle S, Planque S, Taguchi H, Salas M, Nishiyama Y, Handy BC, Hunter R, Edmunson A, Hanson C. Naturally occurring proteolytic antibodies: Selective immunoglobulin M-catalyzed hydrolysis of HIV gp120. The Journal of Biological Chemistry 279:39611-39619, 2004. e-Pub 2004. PMID: 15269209.
- Alexanian R, Weber D, Delasalle K, Handy BC, Champlin R, Giralt S. Clinical outcomes with intensive therapy for patients with primary resistant multiple myeloma. Bone Marrow Transplantation 34:229-234, 2004. e-Pub 2004. PMID: 15170166.
- Handy BC. Urinary beta-2 microglobulin masquerading as a Bence Jones protein. Archives of Pathololgy and Laboratory Medicine 125:555-557, 2001. e-Pub 2001. PMID: 11260637.
- Dasgupta A, Handy BC, Datta P. Mathematical models to calculate fosphenytonin concentrations in the presence of phenytonin using phenytoin immunoassays and alkaline phosphatase. American Journal of Clinical Pathology 113:87-92, 2000. e-Pub 2000.
Invited Articles
- Handy BC, Handy DR. Running with Sjogren's syndrome. Journal of the American Medical Athletic Association (AMAA Journal) Winter:25(1):11, 2012. e-Pub 2012.
- Handy BC. Conference Scene. Advancing toward personalized medicine - Accelerating Development and Advancing Personalized Therapy (ADAPT) Congress. Washington, DC, USA, 22-25 September 2009. Biomarkers in Medicine 4(1):129-131, 2010. e-Pub 2010.
- Handy BC. The clinical utility of tumor markers. Laboratory Medicine 40(2):99-103, 2009. e-Pub 2009.
- Handy BC. Clinical applications of nanotechnology to cancer diagnostics and therapeutics. Journal of the Clinical Ligand Assay Society, Fall:124-129, 2006. e-Pub 2006.
Professional Educational Materials
- Schwartz J, Handy BC. Saliva: The specimen of choice for the future? Check sample. American Society of Clinical Pathologists, Clinical Chemistry. No. CC 96-4(CC-272) 36(4), 1996.
- Handy BC, Perkins A. Continuous photoprocessing and photoprocessing control career ladders, AFS 233X0/X1. United States Air Force Occupational Survey Report, ADA116914, LPN-AFPT-90-233-436, 1982.
- Handy BC. Integrated avionics computerized test station and component (F/FB-111) career ladder, AFS 326X4A. United States Air Force Occupational Survey Report, ADA115991, LPN-AFPT-90-326-428C, 1982.
- Handy BC. Integrated avionics computerized test station and component (F-15) career ladder, AFS 326X4B . United States Air Force Occupational Survey Report, ADA115990 LPN-AFPT-90-326-428C, 1982.
- Handy BC. Integrated avionics computerized test station and component (F-16) career ladder, AFS 32634C, 32654C, and 32674. United States Air Force Occupational Survey Report. ADA115992, LPN-AFPT-90-326-428D, 1982.
Abstracts
- Handy B, Jones P, Jr OR, Schuetz P, Schwabe A, Johannes S, Sherman J, Shapiro NI. Validation of the Elecsys BRAHMS procalcitonin assay in patients with severe sepsis or septic shock. Presented at the Society of Critical Care Medicine Annual Meeting, Honolulu, Hawaii, 2017. e-Pub 2017.
- Cao L, Lee C, Ning J, Handy B, Wagar E, Meng Q. Combining prostate cancer antigen 3 (PCA3) and prostate-specific antigen (PSA) improves diagnostic accuracy in men at risk of prostate cancer. Presented at the American Association for Clinical Chemistry Annual Meeting, Philadelphia, Pennsylvania, 2016. e-Pub 2016.
- Cao L, Maloy C, Munson S, Handy B, Wagar E, Meng Q. Performance evaluation of mycophenolic acid (MPA) on Siemens Dimension Xpand. Presented at the American Association for Clinical Chemistry Annual Meeting, Philadelphia, Pennsylvania, 2016. e-Pub 2016.
- Chen M, Handy BC, Wagar EA, Meng Q. Laboratory investigation of spurious hyperkalemia. Presented at the American Association for Clinical Chemistry Annual Meeting, Chicago, Illinois. e-Pub 2014.
- Chen M, Handy BC, Wagar EA, Meng Q. Factual of fictitious hypocalcemia. Presented at the American Association for Clinical Chemistry Annual Meeting, Chicago, Illinois, 2014. e-Pub 2014.
- Chen M, Handy BC, Wagar EA, Meng Q. Investigation on causes and impact of specimen rejection in the clinical chemistry laboratory. Presented at the American Association for Clinical Chemistry Annual Meeting, 2014. e-Pub 2014.
- Sherman SI, Michaelis C, Gornet T, Handy B, Waguespack SG, Hu M, Busaidy N, Jimenez C, Cabanillas ME, Cote G. Overall survival is reduced in patients with detectable circulating tumor cells from metastatic medullary thyroid cancer. Presented at the 83rd Annual Meeting of the American Thyroid Association, San Juan, Puerto Rico, 2013. e-Pub 2013.
- Vernet MA, Apple F, Handy B, Venge P, Guo VY, Dufoix-Cusin S, Incaurgarat B, Hausmann M. Clinical Performance of VIDAS Galectin-3: predictive value for mortality and hospitalization in a multinational trial in heart failure. Presented at the Annual Meeting of the Heart Failure Association of the European Society of Cardiology, Lisbon, Portugal, 2013. e-Pub 2013.
- Giuliano M, Giordano A, handy BC, Ueno NT, alvarez RH, Hortobagyi GN, Reuben JM, Valero V, Cristofanilli M. Prognostic value of circulating tumor cells (CTC) in HER-2 positive metastatic breast cancer patients treated with antiHER-2-based therapy. Presented at the 33rd Annual San Antonio Breast Cancer Symposium, 2010. e-Pub 2010.
- Giuliano M Giordano A, Handy BC, Ueno NT, Alvarez RH, Hortobagyi GN, Reuben JM, Valero V, Cristofanilli M. Circulating tumor cells (CTC) as predictors of metastatic disease spread in patients with breast cancer. Presented at the 33rd Annual San Antonio Breast Cancer Symposium, 2010. e-Pub 2010.
- Giordano A, Giuliano M, Handy BC, Ueno NT, Alvarez RH, Cohen EN, Andreopoulou E, Hortogagyi GN, Valero V, Cristofanilli M. Clinical value of circulating tumor cells (CTC) in first-line metastatic breast cancer according to type of treatment and immunohistochemical molecular subtype. Presented at the 33rd Annual San Antonio Breast Cancer Symposium, 2010. e-Pub 2010.
Book Chapters
- Handy BC. Laboratory Investigation. In: Medical Care of Cancer Patients. Shelton, CT: BC Decker Inc, 128-132, 2009.
- Alan HB. Contributor to - Proteins, General Clinical Tests Section. In: Tietz Clinical Guide to Laboratory Tests. 4th Edition. W.B. Saunders, 2006.
Letters to the Editor
- Peacock WF, Baumann BM, Rivers EJ, Davis TE, Handy BC, Jones CW, Hollander JE, Limkakeng AT, Mehrotra A, Than M, Cullen L, Ziegler A, Dinkel-Keuthage C. Using Sex-specific cutoffs for high-sensitivity cardiac troponin T to diagnose acute myocardial infarction. Academic Emergency Medicine. Academic Emergency Medicine 28: 463-466, 2021.
- Meng QH, Handy BC, Wagar E. Falsely elevated tacrolimus concentrations on the Dimension Xpand. Clinical Biochemistry 48: 1210, 2015.
- Meng QH, Handy B, Wagar E. Confirmatory testing of urine ketones and bilirubin: still necessary?. Archives of Pathology and Laboratory Medicine 137: 1028 - 1029, 2013.
Patient Reviews
CV information above last modified July 22, 2026